While most experts agree that patients with advanced follicular non-Hodgkin lymphoma who present with symptoms should receive treatment, there are still differing opinions on what therapy to use as first-line treatment, according to an editorial published in the Journal of Clinical Oncology. Research supports the use of rituximab in combination with other drugs, but radioimmunotherapies such as Zevalin and Bexxar also have a potential role in treatment, according to the editorialists. Even with access and reimbursement challenges, these radioimmunotherapeutics are "probably the most effective, yet least used, treatment for follicular lymphoma," according to Dr. Bruce Cheson from the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington, D.C.

Related Summaries